Cargando…
Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems
Injectable implants with the ability to form in situ are one of the most promising carriers for the delivery of chemotherapeutic drugs to tumor sites. We have reported a novel injectable in situ-forming implant system composed of n-butyl-2-cyanoacrylate (NBCA), ethyl oleate, along with the sol-gel p...
Autores principales: | Zhang, Pengcheng, Tao, He, Yu, Liyang, Zhou, Lixiao, Zhu, Chenggang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170320/ https://www.ncbi.nlm.nih.gov/pubmed/32212935 http://dx.doi.org/10.1080/10717544.2020.1745327 |
Ejemplares similares
-
Protein Arginine Methyltransferase 1 (PRMT1) Selective Inhibitor, TC-E 5003, Has Anti-Inflammatory Properties in TLR4 Signaling
por: Kim, Eunji, et al.
Publicado: (2020) -
Identification
of a Protein Arginine Methyltransferase
7 (PRMT7)/Protein Arginine Methyltransferase 9 (PRMT9) Inhibitor
por: Feoli, Alessandra, et al.
Publicado: (2023) -
Structural and biochemical evaluation of bisubstrate inhibitors of protein arginine N-methyltransferases PRMT1 and CARM1 (PRMT4)
por: Gunnell, Emma A., et al.
Publicado: (2020) -
Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation
por: Dashti, Parisa, et al.
Publicado: (2023) -
Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification
por: Ito, Tatsuo, et al.
Publicado: (2009)